GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,006 DKK | +0.58% |
|
-2.95% | -6.91% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Genmab Q2 2021 confe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
2,006
DKK
Average target price
2,434
DKK
Spread / Average Target
+21.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.91% | 18.53B | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B | |
| -23.23% | 8.57B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S, H1 2021 Earnings Call, Aug 11, 2021
